glp·helper
glphelper.com/tirzepatide/california/santee
Dual GIP / GLP-1 receptor agonistFDA-approved May 2022 (Mounjaro) · November 2023 (Zepbound)Rx · Subcutaneous injection · Once weekly

Tirzepatide
(Mounjaro, Zepbound) in Santee, CA

Dr. Fahad Akhtar, M.D.
Medically reviewed by Dr. Fahad Akhtar, M.D.
Physician at g1v.me, an affiliated practice

Physicians near Santee, CA from the federal NPI registry. Ask each office whether it prescribes Mounjaro or Zepbound.[9]

  • Mounjaro: FDA-approved for type 2 diabetes.
  • Zepbound: FDA-approved for chronic weight management, and obstructive sleep apnea with obesity.
city providers
27
as of today

Same molecule (tirzepatide): Mounjaro in Santee, Zepbound in Santee

Other GLP-1 medicines: Ozempic in Santee, Wegovy in Santee, Semaglutide in Santee

§ 02Provider directory: California
27 of 27 shown

Find a physician in Santee.

Every entry comes from the federal NPI registry. Ask each office what it prescribes. We do not accept payment for placement.

Filter →
Type
Provider
City
Insurance / phone
Tirzepatide by California town, physicians per town
§ 03Getting Tirzepatide in Santee
27 providers · Santee, CA

How to get Tirzepatide in Santee.

27 GLP-1 prescribers and 6 local resource types are on record for Santee, plus 3 nearby towns in the directory.

Physicians in Santee
27 physicians
27 physicians from the federal NPI registry in Santee, most listed as Family Medicine (14), Internal Medicine (10) and Nurse Practitioner, Family (1). A licensed clinician who evaluates you decides whether an FDA-approved GLP-1 fits. Telehealth rules vary by state. The nearest towns on record are El Cajon (27 providers), La Mesa (31 providers) and Spring Valley (20 providers).
Around the prescription in Santee
6 listed nearby
14 dietitians, 6 gyms, 6 fitness clubs, 3 trainers, 3 physiotherapists and 22 places to move are on record near Santee.
Medicaid (weight loss)
Diabetes only
As of April 2026, California Medicaid covers GLP-1s for diabetes but not for weight loss. Employer and private plans can still cover them; that is a plan-design choice, not a state rule.

Medicaid status above is for weight-loss use and was compiled April 2026 from KFF and public Medicaid trackers; only 13 states cover it and several are mid-change, so confirm California’s current Medicaid and plan rules before booking. GLPHelper provides information and provider matching, not medical or coverage advice.

§ 04Medication factsheet
cited · last review 2026.05.19

The molecule in Mounjaro and Zepbound. It acts on two gut-hormone pathways, GIP and GLP-1.

Tirzepatide is a once-weekly injection sold by Eli Lilly as Mounjaro (for type 2 diabetes) and Zepbound (for chronic weight management). It is the first approved dual GIP/GLP-1 receptor agonist. It activates two gut-hormone pathways rather than one, which is associated with greater average weight loss than single GLP-1 agonists.[2][3]

In SURMOUNT-1, adults with obesity (without diabetes) lost a mean of 20.9% of body weight on the 15 mg dose at 72 weeks, versus 3.1% on placebo. In the SURPASS-2 head-to-head diabetes trial, tirzepatide produced larger HbA1c and weight reductions than semaglutide 1 mg.[1]

Bar chart of Tirzepatide dose strengths on the FDA label: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg
Tirzepatide comes in 6 strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg. The chart shows what the label lists. A prescriber sets the dose.[1]
At a glanceMultiple (brand-specific)
Active ingredient
tirzepatide
Drug class
Dual GIP / GLP-1 receptor agonist
Manufacturer
Eli Lilly
FDA approved
May 2022 (Mounjaro) · November 2023 (Zepbound)
Approved use
Type 2 diabetes (Mounjaro) · chronic weight management (Zepbound)
Off-label use
Use outside the approved brand/indication is off-label
Administration
Subcutaneous injection · Once weekly
Available doses
2.5 mg · 5 mg · 7.5 mg · 10 mg · 12.5 mg · 15 mg
Half-life
≈ 5 days
Pregnancy
Discontinue ≥ 2 months before a planned pregnancy; may reduce oral contraceptive efficacy

Community health · CDC

Weight & metabolic health in Santee

Santee, California has a population of 60,037 people. The adult obesity rate in Santee is an age-adjusted estimate of 25.9%, 3.2 percentage points below the California state rate of 29.1%. Diagnosed diabetes reaches 8.4% of adults in Santee. Inactivity, meaning no leisure-time physical activity reported in the past month, affects 19% of adults in Santee.

of Santee adults have obesity
25.9%
diagnosed diabetes
8.4%
no regular physical activity
19%

Age-adjusted estimates for Santee, community figures, not individual risk. CDC PLACES, 2025 release.

Estimate your weight lossOzempic side effects in men
§ 05Support around Tirzepatide in Santee
6 fitness clubs

The prescription is one part. Here is the rest, in Santee.

Trials of tirzepatide paired the drug with diet counseling and regular activity. Every name below is a real listing near Santee, CA, ordered as the registry lists them, never by who pays us.

Fitness clubs and recreation centers

Fitness clubs and recreation centers run classes and pools, an easier start than a weight room.

Cameron Family YMCA
FITNESS
4.0 on Google · 349 reviews
10123 Riverwalk Dr
Website
Shape 360 Fitness Studio
FITNESS
5.0 on Google · 74 reviews
7945 Mission Gorge Rd Unit 102
Website
CrossFit Dark Side
FITNESS
4.9 on Google · 73 reviews
11421 Woodside Ave # C
Website
Wise Owl Fit
FITNESS
5.0 on Google · 7 reviews
9225 Carlton Hills Blvd #28
Website
Planet Fitness
GYM
4.4 on Google · 753 reviews
12419 Woodside Ave
Website
Chuze Fitness
GYM
4.6 on Google · 640 reviews
215 Town Center Pkwy
Website

Registered dietitians

A registered dietitian builds the food plan around your prescription. Call to ask about GLP-1 nutrition plans and insurance.

Cindy Almestica, R.D
RD
Registered dietitian
9065 Edgemoor Dr
Call 619-956-2964NPI 1760504708
Natalie Beattie, RDN
RD
Registered dietitian
7735 Mission Gorge Road Space 48
Call 949-636-7482NPI 1114688371
Phillip Corona, RD
RD
Registered dietitian
9095 Prospect Ave Apt 207
Call 760-996-3817NPI 1073466496
Andrew Gehr
RD
Registered dietitian
250 Prospect Pl
Call 805-630-4671NPI 1760349310
Chelsea Gelina, RD
RD
Registered dietitian
1302 Calabria St
Call 619-701-7272NPI 1508249954
Paulina Giba, Registered Dietitian
RD
Registered dietitian
655 Park Center Dr
Call 619-596-5500NPI 1003467192
§ 06Clinical evidence
STEP 1 to 4 + SELECT (N = 17,604)

What the trials actually showed.

We summarize the SURMOUNT weight-management program and the SURPASS diabetes program, including the SURPASS-2 head-to-head against semaglutide. Figures are means at each trial's primary endpoint.

SURMOUNT-1 randomized 2,539 adults with obesity (without diabetes) across 72 weeks. Mean weight change was −15.0% (5 mg), −19.5% (10 mg), and −20.9% (15 mg) versus −3.1% with placebo. A majority of patients on the higher doses lost ≥20% of body weight.[2]
STEP / SELECT endpoint table2.4 mg / 68 wk
Mean weight change (15 mg)
−20.9%
SURMOUNT-1, 72 wk vs −3.1% placebo[2]
Mean weight change (5 mg)
−15.0%
SURMOUNT-1, 72 wk[2]
HbA1c reduction (T2D)
−1.8 to −2.6%
SURPASS program[4]
vs. semaglutide 1 mg
Superior
SURPASS-2, HbA1c + weight[3]
Effect size varies with baseline characteristics and adherence. Individual response may differ materially.
average tirzepatide weight loss →mapped to your starting weight
§ 07Safety & adverse events
from FDA label, sect. 6.1

Most Tirzepatide side effects are stomach and gut effects.

In Zepbound's weight trials at 5 to 15 mg, the most common side effects were nausea (25 to 29%), diarrhea (19 to 23%), constipation (11 to 17%), and vomiting (8 to 13%). Mounjaro's diabetes trials showed lower rates at the same doses.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[1]

Boxed warning. Boxed warning: risk of thyroid C-cell tumors. Contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).
Effect
Frequency
Severity
Note
Nausea
12 to 29%
mild
Lowest on Mounjaro 5 mg, highest on Zepbound 10 mg
Diarrhea
12 to 23%
mild
More frequent during dose escalation
Vomiting
5 to 13%
mild
Reduced by slower titration
Constipation
6 to 17%
mild
Decreased appetite
5 to 11%
mild
Reported in Mounjaro's diabetes trials
Pancreatitis
<0.3%
serious
Discontinue if acute pancreatitis is suspected
Gallbladder disease
~1 to 2%
serious
Cholelithiasis risk rises with rapid weight loss
Thyroid C-cell tumors
rodent data
boxed warning
Contraindicated with MTC or MEN-2 history
§ 08Cost & coverage, published, not gated
USD · monthly

What Tirzepatide costs, by how you pay.

The price you pay depends on your insurance plan, your diagnosis, and how you buy. Manufacturer self-pay programs cost far less than pharmacy retail. Here are the ranges.

Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Eli Lilly self-pay and savings pages.

Self-pay and savings card prices checked . Retail averages from May 2026.

Tirzepatide monthly cost by how you pay
Zepbound, pharmacy retail$1,000 to $1,300per monthBrand-name retail average, May 2026[6]
Zepbound, LillyDirect self-pay$299 to $699per monthKwikPen by dose: 2.5 mg $299, 5 mg $399, 7.5 mg $499, 10 to 15 mg $699. The $449 offer on 7.5 to 15 mg applies to the first purchase and to refills within 45 days. Vials start at $299
Mounjaro, pharmacy retail$1,000 to $1,200per monthBrand-name retail average, May 2026[6]
Commercial insurance (T2D)$25 to $250per month copayUsually covered for diabetes with prior authorization
Commercial insurance (weight)Often deniedZepbound is on-label but frequently requires PA
Medicare Part D$0 to $100per monthType 2 diabetes covered. Zepbound KwikPen for weight management is $50 a month through the Medicare GLP-1 Bridge, Jul 2026 to Dec 2027[5]
Manufacturer savings cardas low as $25per monthCommercial insurance only; eligibility limits apply
Find Tirzepatide providers in Santee

Physicians from the federal NPI registry. Ask each office whether it prescribes Tirzepatide.

Tirzepatide in other states

Physicians from the federal NPI registry in the states we cover. Ask each office whether it prescribes Tirzepatide.

Related GLP-1 research
§ 09Frequently asked: Tirzepatide in California

The questions people ask before they book.

Answers reviewed by the glp·helper Medical Team. Citations link to primary sources, never marketing copy.

Tirzepatide is the active ingredient in two Eli Lilly brands: Mounjaro and Zepbound. No generic tirzepatide is FDA-approved in the US. Mounjaro is approved for type 2 diabetes; Zepbound is approved for chronic weight management. They share an active ingredient but carry different approved indications, and insurers treat them as separate products.[1]